ArticleInfectious agents and cancer2026
HIV-associated malignancies in Tunisia: a 30-year retrospective cohort study from a North African perspective.
Article in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite major advances in antiretroviral therapy (ART), HIV-associated malignancies remain a significant cause of morbidity and mortality in low- and middle-income countries. In Tunisia, data on AIDS-defining cancers (ADCs) and non-AIDS-defining cancers (NADCs) among people living with HIV (PLWH) remain scarce.
methodsWe conducted a descriptive retrospective cohort study over a 30-year period (1994-2024) at Farhat Hached University Hospital, Sousse, Tunisia. All PLWH who developed at least one malignant neoplasm were included. Epidemiological, clinical, immunovirological, pathological, and outcome data were retrospectively collected and analyzed.
resultsAmong 655 PLWH followed during the study period, 25 patients with a median age of 36 years developed malignancies, representing 3.8% of all PLWH. 27 malignancies were identified with 2 patients developing 2 distinct malignancies: a Kaposi sarcoma (KS) and a Non-AIDS-defining cancer (NADC). AIDS-defining cancers (ADC) predominated (81.5%), mainly KS (44.4%) and non-Hodgkin lymphoma (33.3%), while NADCs accounted for 18.5%. Cancer and HIV diagnoses were concomitant in 56% of patients (n = 14) and 92% of malignancies occurred within the first year following HIV diagnosis. Most patients presented with advanced immunodeficiency, with median CD4 counts at tumor diagnosis of 73 cells/mm³ for ADCs and 57 cells/mm³ for NADCs. Median overall survival was 1.9 years for ADCs and 3.7 years for NADCs.
conclusionsIn this North African cohort, HIV-associated malignancies were predominantly AIDS-defining cancer and affected young adults with advanced immunosuppression, reflecting late HIV diagnosis for PLWH developing malignancies. Beyond strengthening early HIV testing and timely ART initiation, targeted patient education focusing on high-risk behaviors, along with efforts to reduce HIV-related stigma, are essential components to improve cancer prevention, early diagnosis, and outcomes among PLWH in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.